Abstract
Introduction: postmenopausal osteoporosis (PMOP) is a common bone disorder. Zoledronic acid and denosumab are widely utilized in the treatment of osteoporosis. This work aimed to explore the clinical effects and changes in serum inflammatory cytokine (IFC) levels of zoledronic acid and denosumab in the therapy of PMOP.Materials and Methods: eighty PMOP patients who visited our hospital from March 2021 to March 2024 were recruited and rolled into a control group (CG, n=40) and a treatment group (TG, n=40). CG received zoledronic acid plus traditional treatment, while TG received zoledronic acid plus denosumab plus traditional treatment. Clinical symptom improvement and changes in bone mineral density (BMD) were recorded and compared between the two groups. Changes in serum IFC levels were measured.Results: relative to CG, patients in TG showed greatly increased BMD (P<0.05), and markedly decreased levels of serum IFCs, bone Gla protein (BGP), and bone turnover markers β-collagen degradation product (β-CTX), and procollagen type 1 N-terminal propeptide (P1NP) (P<0.05). Additionally, the incidence of adverse reactions was drastically lower (P<0.05) in TG, and the total effective rate of clinical treatment was notably higher (P<0.05).Conclusion: zoledronic acid combined with denosumab demonstrates good clinical efficacy in PMOP patients, improving clinical symptoms and promoting increased BMD. Furthermore, this combined treatment regimen can reduce serum IFC levels, possibly promoting the treatment of osteoporosis by suppressing inflammatory responses.
Keywords
References
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.